A61K31/39

PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF

The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF

The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Selective extraction method for natural substances

An extraction method for nonpolar natural substances includes: a step of conducting extraction of natural raw materials to prepare a first liquid extract; a step of mixing the first liquid extract with a phase separation composition containing a lipophilic solubilizer and water, and conducting a second extraction; and a step of isolating the supernatant of the phase-separated solution to obtain non-polar natural substances.

INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR

The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.

INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR

The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.

SELECTIVE EXTRACTION METHOD FOR NATURAL SUBSTANCES

An extraction method for nonpolar natural substances includes: a step of conducting extraction of natural raw materials to prepare a first liquid extract; a step of mixing the first liquid extract with a phase separation composition containing a lipophilic solubilizer and water, and conducting a second extraction; and a step of isolating the supernatant of the phase-separated solution to obtain non-polar natural substances.

Antibacterial sideromycins

A compound, comprising: an Fe(III)-binding and/or Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; and daptomycin covalently bound to the linker, or, if no linker is present, then to the siderophore; or pharmaceutically acceptable salt or solvate thereof.

ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER
20210283100 · 2021-09-16 ·

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject a therapeutically effective amount of: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) a sodium glucose cotransporter inhibitor, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER
20210283100 · 2021-09-16 ·

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject a therapeutically effective amount of: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) a sodium glucose cotransporter inhibitor, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENS

A field of biological fungicides with a broad range of antifungal activity coming from plant extracts from the order of Brassicales or molecules revealing similar chemical structure. In particular, Applicants surprisingly provided a new usage of a combination of sulfonyl and sulfinyl containing aliphatic glucosinolates, their by-products and synthetic analogues as efficient antifungal compounds with broad spectrum of activity.